RAT 13: PD and Alzheimers AW

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/105

encourage image

There's no tags or description

Looks like no tags are added yet.

106 Terms

1
New cards

Medication classes for AD

-Cholinesterase inhibitors

-NMDA receptor antagonist

-Combo

-Anti-amyloid monoclonal antibody therapy

2
New cards

Cholinesterase inhibitors

-Donepezil (patch)

-Galantamine

-Rivastigmine (patch available)

3
New cards

NMDA antagonists

-Memantine

4
New cards

Combo drug

-Memantine/donepezil

5
New cards

Anti-anyloid monoclonal antibody therapy

-Lecanemab

-Donanemab

6
New cards

Goals of therapy

-There is no cure

-Delaye disease progression and preservation of functioning as long as possible

-Treating psychiatric and behavioral symptoms that may occur during the course of the disease

7
New cards

General pathophys

-Abnormal proteins

-Decreased NTs

-Genetics

8
New cards

Abnormal proteins

-High amyloid-beta plaques and tau tangles

-Both cause neurodegeneration

9
New cards

NTs in AD

-Ach

-Glutamate

10
New cards

Ach in AD

-Plaques and tangles damage acetylcholine

-Shortage of Ach impairs learning and memory

-This is the background for treatment with acetylcholinesterase inhibitor

11
New cards

Glutamate in AD

-Primary excitatory NT

-Involved in memory, learning, and neuronal plasticity

-Glutamate receptor N-methyl-D-aspartate (NMDA) is less prevalent in AD

-Overactivation of unregulated glutamate signaling

-Rise in Ca ions that induce secondary cascades, leading to neuronal death and increased APP causing more plaques and tangles

12
New cards

Early onset AD

-AD prior to age 60

-Approx 1% of AD

-Usually familial: autosomal dominant

13
New cards

Late onset AD

-Genetic susceptibility is more sporadic

-More dependent on environment

-Apo E gene on chromosome 19: strong risk factor for late onset

14
New cards

Symptoms of mild neurocognitive disorder

-Mild decline in cognitive function and modest impairment in cognitive performance (usually via testing)

-Don't interfere with everyday activities

15
New cards

Symptoms of moderate neurocognitive disorder

-Significant decline in cognitive function and substantial impairment in cognitive performance (usually via testing)

-Interfere with independence in everyday activities

16
New cards

Diagnostic criteria for AD

-Criteria met for neurocognitive disorder

-Insidious onset, gradual progression

-Clear evidence of decline

-Steadily progressive without plataues

-Major: Evidence of genetics, probable AD diagnosed

-Mild: possible AD diagnosed

17
New cards

When to initiate pharm therapy

-ASAP after diagnosis

18
New cards

Treatment for mild AD

-Acetylcholinesterase inhibitor

19
New cards

Treatment for moderate-to-severe AD

0Acetylcholinesterase inhibitor, memantine, or combo

20
New cards

Expectations from pharm therapy

-Emphasis should be on helping to maintain a therapeutic living environment while minimizing the burden of care resulting from the disease

21
New cards

When to use antibody therapy

-After confirmation of the presence of amyloid beta pathology and obtainment of a recent brain MRI

-Can be done with mild cognitive impairment

22
New cards

Unconventional AD treatments

-Vitamin E: at

23
New cards

Lifestyle mods

-Music

-Videos of family

-Audiotapes of caregivers

-Walking and light exercise

-Sensory stimulation and relaxation

24
New cards

Behavioral and psychological symptoms of AD

-Agitation

-Aggression

-Anxiety

-Psychosis

25
New cards

Medications for behavioral and psychological symptoms

-See if AChE inhibitors work

-Antipsychotics: brexpiprazole (increased mortality with other antipsychotics)

-Anticonvulsants (conflicting evidence)

-Buspirone

-Selegiline (not well tolerated)

-Trazodone (good for sundowning)

26
New cards

Medication class for depression in AD

-SSRIs

-Avoid anticholinergic antidepressants

27
New cards

Benzos in AD

-For anxiety, agitation, and aggression

-Concern of fall risk

28
New cards

Length of trial for AChE inhibitors

-Need to allow a trial for effectiveness for 3-6 months

-

29
New cards

Common AChE inhibitor adverse effects

-N/V/D

-Headache

-Dizziness

-Muscle cramps

-Insomnia

-Fatigue

-Anorexia

-Depression

30
New cards

Major AChE inhibitor adverse effects

-Anorexia

-Weight loss

-Falls

-Hip fractures

-Syncope

-Bradycardia

-Increased use of cardiac pacemakers

31
New cards

If intolerability

-Shoulds witch from one AChE to another AChE

32
New cards

ARIA

-Brain edema (ARIA-E)

-Microhemorrhage (ARIA-H)

-Detected through monitored imaging

-Symptoms can include headaches, vomiting, confusion, gait disturbance

33
New cards

ARIA monitoring

-MIR required if receiving antibody therapy

34
New cards

Donepezil adverse effects

-N/V/D

-Headache

-Dizziness

-Muscle cramp

-Insomnia

-Fatigue

-Anorexia

-Depression

-Weird dreams

-Weight decrease

35
New cards

Donepezil titration

-Starting: 5 mg in evening

-Maintenance: 5-23 mg

-Adjust over months

-No adjustment for renal/hepatic

36
New cards

Galantamine adverse effects

-N/V/D

-Headache

-Dizziness

-Insomnia

-Fatigue

-Anorexia

-Depression

-Abdominal pain

37
New cards

Galantamine titration

-Starting: 4 BID if IR, 8 daily if ER

-Maintenance: 8-12 BID if IR, 16-24 daily if ER

-Titrate every 4 weeks

38
New cards

Galantamine Pkinetics

-Don't exceed 16 mg for moderate hepatic or renal impairment

-Dont administer in severe hepatic or renal impairment

39
New cards

Rivastigmine adverse effects

-N/V/D

-Headache

-Dizziness

-Insomnia

-Fatigue

-Anorexia

-Depression

-Weight decrease

-Abdominal pain

40
New cards

Rivastigmine titration

-Starting: 1.5 BID (oral), 4.6mg daily (patch)

-Maintenance: 3-6 BID (oral), 9.5 daily (patch

-Oral: titrate over 2 weeks

-Patch: titrate over 4 weeks

41
New cards

Rivastigmine Pkinetics

-Max dose 4.6 mg/day if moderate to severe renal impairment or mild-moderate heapatic impairment or low body weight (

42
New cards

Memantine adverse effects

-V/D

-Headache

-Dizziness

-Fatigue

-Depression

-Abdominal pain

43
New cards

Memantine titration

-Starting: 5m daily IR or 7 mg daily ER

-Maintenance: 10 mg BID IR or 28 mg daily Er

-Over 1 week

44
New cards

Memantine Pkinetics

-Don't exceed 14 mg daily (or 5 mg BID) in severe renal impairment

45
New cards

Antibody therapy adverse effects

-Diarrhea

-Headache

-ARIA-E or H

-Falls

-Infusion related reactions

-Cough

-Confusion

46
New cards

Antibody therapy titration

-10 mg/kg every 2 weeks

-No titration necessary

-No change in renal/hepatic impairment

47
New cards

Drug classes for PD

-Anticholinergics

-MAO-B inhibitors

-Amantadine

-DA agonists

-Sinimet

-COMT inhibitors

-Combo

-Istradefylline

-Pimavanserin

-Droxidopa

48
New cards

Anticholinergics

-Benztropine

49
New cards

MAO-B inhibitors

-Safinamide

-Selegiline

-Rasagiline

50
New cards

DA inhibitors

-Ropinirole

-Rotigotine

-Pramipexole

-Apomorphine

51
New cards

COMT inhibitors

-Tolcapone

-Entacapone

-Opicapone

52
New cards

Primary NT affected

-Decrease in DA in the s. nigra for movement

53
New cards

Primary NT target for PD for drug therapy

-DA

54
New cards

Drugs that can cause drug-induced PD

-Antipsychotics

-Metoclopramide

-Antiemetics

55
New cards

3 cardinal motor findings for PD

-Tremors at rest

-Rigidity

-Akinesia/bradykinesia

-Bonus: postural instability

56
New cards

Common nonmotor symptoms in PD

-Depression, anxiety

-Impulse control

-Paranoia, delusions, visual hallucination

-Constipation, gastroparesis, dysphagia

-Sleep

-Sensory

-Speech symptoms

57
New cards

When should PD medications be initiated

-When symptoms become bothersome

58
New cards

Health care members important in PD

-Dietician

-Speech therapist

-PT or OT

59
New cards

DIetician in PD

-Recommend appropriate caloric intake, meal selection, and protein consumption

-Improves constipation, nausea, weight maintenance, aspiration risk

-Minimizes erratic drug absorption

60
New cards

Speech therapist in PD

-Swallowing, speech volume and articulation, facial expression

-Minimize risk of aspiration and improve communication

61
New cards

PT and OT in PD

-Posture, balance, strength, gait, stamina

-Increases physical activity and reduces fall risk

-Maximize independence at home

62
New cards

Medication for initial treatment of motor symptoms

-Levodopa

63
New cards

When to consider DA or MAO-B

-DA:

64
New cards

Older pts

-Should not receive DA if they have hx of impulse control disorder, cognitive impairment, excessive daytime sleepiness, or hallucinations

65
New cards

Levodopa formulations

-CR

-IR

-ER

-Enteral suspension

-Dry powder

66
New cards

CR levodopa

-Less bioavailable

-Longer and more erratic absorption time (2 hours)

-Not interchangeable with IR, but can be added to extend duration

67
New cards

IR levodopa

-More bioavailable

-30 min absorption time

-Not interchangeable with CR

68
New cards

ER levodopa

-More sustained release

-Peaks within 1 hour and is maintained for 4-5 hrs before declining

-Conversion between CR and IR and ER may be imprecise

69
New cards

Enteral suspension levodopa

-Can administer directly into duodenum via tube

-Improves motor fluctuations

-Reserved for advanced PD and severe motor fluctuations

70
New cards

Dry powder levodopa

-Breath actuated inhaler

-Doesn't require drug absorption in GI tract

-Delivered via lung

-Used for intermittent off periods

-Acts within 10 mins and lasts at least 1 hour

-Use up to 5 times daily

71
New cards

Types of OFF episodes

-Wearing off

-Unpredictable off

-Peak-dose dyskinesia

-Off period dystonia

72
New cards

Wearing off

-When carbidopa/levodopa isn't working as well, typically at the end of the dose schedule

73
New cards

Peak dose dyskinesia

-When levodopa is at its maximal efficacy

-Excessive involuntary movements (chorea or dystonia)

74
New cards

How to manage OFF episodes

-Increase dose and frequency of levodopa, but often limited by development of dyskinesias

-Crush and swallow extra 1/2 tab of levodopa right before next dose

-Add COMT, MAOB, DA, istradefylline, or amantadine

-Unique L-dopa formulations

75
New cards

PD depression

-Common (35% or more), possible premotor sign

-TCAs, SSRIs

-Pramipexole!

76
New cards

PD dementia

-80% mof pts after 20 yrs of diagnosis

-Rivastigmine

77
New cards

PD psychosis

-Gradually decrease and stop low-efficacy antiparkinsonian medications

-If this fails, may consider antipsychotics, but will worsen PD

-Pimavanserin!

-Clozapine and quetiapine!

78
New cards

PD sleep problems

-Amantadine and selegiline may worsen insomnia

-Some antidepressants and antipsychotics may worsen RLS

-Rotigotine patch for sleep

-Sleep hygiene

-Doxepin

79
New cards

PD hypotension

-Orthostatic hypotension common

-Droxidopa: NE synthetic precursor

80
New cards

Common side effects of all anti-PD

-N/V

-Hypotension

-Hallucinations

81
New cards

Benztropine MOA

-Anticholinergic

82
New cards

Benztropine dosing notes

-Good for tremor and drooling, but not other symptoms

-Not for elderly

83
New cards

Benztropine adverse effects

-Anything anticholinergic

84
New cards

Selegiline MOA

MAO-B inhibitor

85
New cards

Selegiline dosing notes

-Mild symptomatic benefit as monotherapy

-Manage motor fluctuations and reduce off time with levodopa

86
New cards

Selegiline adverse effects

-Jitteriness

-Insomnia

-Not wel tolerated

87
New cards

Rasagiline MOA

MAO-B inhibitor

88
New cards

Rasagiline dosing notes

-Mild symptomatic benefit as monotherapy

-Manage motor fluctuations and reduce off time with levodopa

89
New cards

Rasagiline adverse effects

-Less likely to cause insomnia

-No tyramine foods (HTN crisis)

90
New cards

Amantadine MOA

-NMDA antagonist that blocks glutamate transmission and promotes DA release

91
New cards

Amantadine dosing notes

-Effective as mono and adjunct therapy for OFF time and levodopa dyskinesias

-ER specifically for dyskinesias

92
New cards

Amantadine adverse effects

-Livedo reticularis

-Peripheral edema

-Restlessness

-Anticholinergic

-Insomnia (better with ER)

93
New cards

D2 agonist dosing notes

-Monotherapy in early PD and as an adjunct to levodopa in advanced cases

94
New cards

D2 agonist adverse effects

-Sedation

-Pedal edema

-Nightmares

-Confusion

-Daytime sleepiness

-Sudden sleep attacks

-ICD

-DDS

-Apomorphine: severe N/V, must premedicate with antiemetic

95
New cards

ICD

-Impulse control disorders

-Gambling, compulsive shopping and sex, excessive hobbying, binge eating

96
New cards

DDS

-DA dysregulation syndrome

-Drug seeking and punding

97
New cards

Punding

-Repetitive handling and examining of mechanical objects

98
New cards

Carbidopa/levodopa MOA

-Levodopa is a precursor of dopamine

-Carbidopa inhibits dopa decarboxylase preventing peripheral metabolism of levodopa

99
New cards

Carbidopa/levodopa dosing notes

-At least 75 mg/day for effectiveness

-Start at very low dose

-May dose q2h in advanced PD

100
New cards

Carbidopa/levodopa adverse effects

-Anorexia

-Discoloration of urine/sweat

-Minimize by taking with low-protein food or slow titration

-Dyskinesias

-Sleep attachs

-ICDs

-Nightmares

-Confusion